Market Pulse Archives

July 15, 2020, 7:34 a.m. EDT

Relay Therapeutics upsizes and raises proposed price range for IPO

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Relay Therapeutics Inc. [s :rlay] upsized and raised its expected price range for its initial public offering on Wednesday, with plans to offer 20 million shares priced at $18 to $19 each. The clinical-stage oncology biotech had previously planned to offer 14.7 million shares, priced at $16 to $18 each. The company has applied to list on Nasdaq, under the ticker symbol "RLAY." JP Morgan, Goldman Sachs, Cowen and Guggenheim are underwriting the deal. Proceeds will be used to fund clinical research and for general corporate purpose, including hiring new workers. "We are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology," the company says in its prospectus.

Get news alerts on Relay Therapeutics Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.